A Randomized, Controlled Trial of Liraglutide for Adolescents with Obesity

Obesity is a chronic disease with limited treatment options in pediatric patients. This randomized, double blind trial evaluated the efficacy and safety of liraglutide (3.0 mg) plus lifestyle therapy versus placebo plus lifestyle therapy in adolescents (12 to <18 years) with obesity. The primary endpoint was the change in BMI standard deviation score at week 56. Liraglutide was superior to placebo, with an estimated difference of 0.22 (95% CI, 0.37 to 0.08; P=0.002). A reduction in BMI of at least 5% was observed in 43.3% of the liraglutide group versus 18.7% in the placebo group. Gastrointestinal adverse events were more common with liraglutide (64.8% vs. 36.5%). The study concluded that liraglutide is effective for weight management in adolescents with obesity but may not be suitable for all due to side effects.

Obesity is a chronic disease with limited treatment options in pediatric patients. This randomized, double blind trial evaluated the efficacy and safety of liraglutide (3.0 mg) plus lifestyle therapy versus placebo plus lifestyle therapy in adolescents (12 to <18 years) with obesity. The primary endpoint was the change in BMI standard deviation score at week 56. Liraglutide was superior to placebo, with an estimated difference of 0.22 (95% CI, 0.37 to 0.08; P=0.002). A reduction in BMI of at least 5% was observed in 43.3% of the liraglutide group versus 18.7% in the placebo group. Gastrointestinal adverse events were more common with liraglutide (64.8% vs. 36.5%). The study concluded that liraglutide is effective for weight management in adolescents with obesity but may not be suitable for all due to side effects.